Monoclonal Antibodies Market Set for Rapid Growth by Top Players | Pfizer, Novartis AG, Bayer AG

Different monoclonal antibodies with unique mechanism of actions have been approved over the past few years, which work on immune checkpoints such as CTLA-4, PD-1, and PD-L1. Manufacturers are focusing on developing drugs belonging to various classes in order to treat variety of diseases ranging from cancer to rare diseases. Monoclonal antibody coupled with chemotherapy agents is becoming a viable treatment option to treat various cancers. For instance, in 2017, the U.S. Food & Drug Administration (FDA) approved Darzalex (daratumumab) in combination with pomalidomide and dexamethasone for the treatment of patients suffering from multiple myeloma, who have received two prior therapies. These factors are expected to support growth of the market over the forecast period.

Rising incidence of cancer and other chronic diseases is a major factor that is expected to boost the monoclonal antibodies market growth over the forecast period. According to GLOBOCAN, in 2018, an estimated 43.6% new cases of breast cancer were registered in Asia Pacific. Also, according to the American Cancer Society, 2017, cancer was the second most common cause of death in the U.S., which accounted for around 1 out of every 4 deaths.

Get Free Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @  https://www.coherentmarketinsights.com/insight/request-sample/2403 

Market players are focused on combining monoclonal antibodies with other therapies such as chemotherapy drugs, which is expected to assist the market growth over the forecast period. For instance, combination of nivolumab and ipilimumab for the treatment of intermediate- or poor-risk patients with previously untreated advanced renal cell carcinoma was approved in the U.S. in 2018 and in January 2019 in Europe.

Moreover, efforts of manufacturers to increase number of indications (oncology) for monoclonal antibodies is further expected to boost the market growth over the forecast period. For instance, in June 2018, the U.S. Food & Drug Administration (FDA) expanded the indication of pembrolizumab (Keytruda) to include recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Key features of the study:

This report provides in-depth analysis of the global monoclonal antibodies market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global monoclonal antibodies market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans

Key companies covered as a part of this study include Pfizer Inc., Novartis AG, Bayer AG, Sanofi S.A., F. Hoffmann-La Roche AG, Eli Lilly and Co., Merck & Co., Inc., GlaxoSmithKline Plc., AbbVie Inc., Bristol-Myers Squibb, and Regeneron Pharmaceuticals Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future launches, market expansion, and marketing tactics

The global monoclonal antibodies market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global monoclonal antibodies market

Buy This Complete A Business Report:  https://www.coherentmarketinsights.com/insight/buy-now/2403 

Company Profiles:

Pfizer Inc.*
Novartis AG
Bayer AG
Sanofi S.A.
Hoffmann-La Roche AG
Eli Lilly and Co.
Merck & Co., Inc.
GlaxoSmithKline Plc.
AbbVie Inc.
Bristol-Myers Squibb
Regeneron Pharmaceuticals Inc.

Detailed Segmentation:

By Source:
Human
Chimeric
Murine
Humanized

By Application:
Cancer
Autoimmune Disease
Hematological Disease
Infectious Disease
Others

By Distribution Channel:
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Coherent Market Insights 1001 4th Ave,
#3200 Seattle, WA 98154,U.S.
Phone: US +1-206-701-6702/UK +44-020 8133 4027
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.